Mark C. Capone is president and CEO of Myriad Genetics. He previously served as president of Myriad Genetic Laboratories from March 2010 to June 2015. Mr. Capone joined the company in October 2002. Prior to joining Myriad, he served 17 years with Eli Lilly and Company where he held positions as product development manager, manufacturing plant manager, and area sales director. Mr. Capone received his B.S. degree in Chemical Engineering from Penn State University graduating with highest distinction and his M.S. degree in Chemical Engineering from Massachusetts Institute of Technology. He also earned a Master of Science in Management from the Sloan School of Management at the Massachusetts Institute of Technology. In 2012, Mr. Capone was elected Outstanding Engineering Alumnus at Penn State and is a member of the Industrial and Professional Advisory Council along with Advisory Board for the Hershey Medical Center for Innovation, both at Penn State. He currently serves on the Board of the American Clinical Laboratory Association and is a Member of the Board of Trustees for Pioneer Theatre Company in Salt Lake City.
Patrick Burke, executive vice president of emerging products, joined the company in 2001. In his current role, he oversees new product planning, business development and project management. Previously, Dr. Burke served as vice president of strategic collaborations and held positions of increasing responsibility within the business and corporate development group at Myriad. Between 2009 and 2011, he served as vice president of corporate and business development at Myrexis, Inc., a subsidiary of the company. Dr. Burke is an active member of Licensing Executive Society and the Association of University Technology Managers. He earned his Ph.D. in Cell Biology from the University of Utah School of Medicine and his B.A. in Molecular Biology from the University of California, San Diego.
Bryan M. Dechairo, executive vice president of Clinical Development, joined the company in August 2012. Before being named to his current position, he served as CSO, CMO and SVP of R&D at Assurex Health. Prior to joining Myriad, Dr. Dechairo was the head of diagnostic reimbursement evaluation and extramural research and development for Medco Health Solutions. He also served as the neuroscience lead and director of molecular medicine at Pfizer Global Research and Development. Dr. Dechairo earned a Ph.D. in Common Complex Human Genetics from the Institute of Child Health at University College London and a B.A. in Integrative Biology from the University of California, Berkeley.
Alexander Ford, president of Myriad Genetic Laboratories, joined the company in June 2010. Before being named to his current position, he served as chief commercial officer. Prior to joining Myriad, Mr. Ford held leadership positions at Novartis, Sanofi-Aventis, Nektar Therapeutics and Pfizer in the areas of marketing research, product marketing, managed care, sales and business development. He has more than 25 years of experience in the pharmaceutical and biotechnology industries. Mr. Ford received his B.A. degree in Communications from the University of North Carolina, Wilmington and his M.A. degree from New York University. He was a founding board member for BioUtah and was voted sales executive of the Year by the Utah Technology Council in 2012.
Robert G. Harrison, chief information officer, joined Myriad in 1996. He served as Myriad's network administrator from 1996 to 2000 and was named director of information systems and technology in 2000. Mr. Harrison was named vice president of information systems and technology in 2005, a position he held until January 2008 when he was named chief information officer. He began his career in IT working for several private companies and consulting firms where he held positions in technical support, sales and management roles. Mr. Harrison received a B.S. degree in Business Administration with a minor in Computer Science from the University of Utah in 1994.
Jayne B. Hart joined Myriad in May 2011 as executive vice president of human resources. She has more than twenty years of professional experience in the human resources field. Prior to joining Myriad, Ms. Hart served as vice president of human resources at LANDesk Software, a global software company. Before that, she was vice president of human resources for 360networks, a wholesale telecommunications company, and at AT&T Wireless, a global telecommunications company, where she began her career.
Gary A. King joined Myriad in July 2010. He has been employed in the life sciences industry for more than 25 years. Most recently, he was the chief executive officer of AverDx Inc., an international Biotechnology Company. Prior to AverDx, Mr. King was vice president of international operations at Biosite Inc. where he spent six years building and leading all of the Company's commercial activities outside of the United States. He established marketing and logistics operations in Germany, France, Italy, the United Kingdom, Netherlands and Belgium, and formed clinical operations and marketing programs in Asia. Prior to joining Biosite, he was division director in Japan for Guidant Corporation and led Guidant's transition from distributor to direct operations in the Japanese market. Mr. King received his B.A. degree in Zoology from Pomona College and an M.B.A. degree from Stanford University.
Johnathan M. Lancaster, M.D. Ph.D, chief medical officer, joined Myriad in 2015 as vice president of Medical Affairs, and shortly thereafter was appointed chief medical officer for Myriad Genetic Laboratories, where he provided medical and scientific leadership across Myriad's expanding portfolio of precision medicine products and services. Dr. Lancaster is an internationally recognized expert in gynecologic oncology and personalized medicine, and has published over a hundred peer-reviewed scientific manuscripts. Prior to joining Myriad, Dr. Lancaster was professor of obstetrics & gynecology and oncologic sciences at the University of South Florida, and held leadership positions at Moffitt Cancer Center, including president of the Moffitt Medical Group, director of the Center for Women's Oncology, and chair of the Department of Women's Oncology. He directed Moffitt's translational research laboratory program in gynecologic oncology. Dr. Lancaster earned his medical and research doctoral degrees in molecular genetics from the University of Wales, U.K., and underwent residency training at the University of Cambridge in England and Duke University Medical Center in Durham, NC, where he also completed his fellowship in gynecologic oncology. He is board certified in both obstetrics & gynecology and gynecologic oncology.
Jerry Lanchbury, chief scientific officer, joined Myriad in September 2002. Before that, he was a researcher in molecular immunogenetics at Kings College London. He is a highly respected expert in immunogenetics with more than 100 reviewed research journal publications. Dr. Lanchbury graduated from the University of Aston, Birmingham, U.K. He earned his Ph.D. in Population Genetics from the University of Newcastle upon Tyne and subsequently completed a postdoctoral fellowship at the United Medical & Dental Schools of the University of London in Human Disease Genetics.
Richard Marsh, executive vice president, general counsel and secretary, joined Myriad in November 2002. Prior to that, he served in various positions at Iomega Corporation including acting general counsel, director of IP and director of commercial legal affairs. Mr. Marsh received an LL.M. degree in Taxation from Georgetown University Law Center; a law degree from Thomas M. Cooley Law School, graduating magna cum laude; and a B.S. degree in Accounting from Brigham Young University. He was formerly a Certified Public Accountant.
Ralph L. McDade is the president of Myriad RBM. Until August of 2013, he had been serving as chief operating officer. Dr. McDade was formerly strategic development officer for Myriad RBM and held that position since the Company's inception in 2002. Prior to joining Myriad RBM, he was chief scientific officer for Luminex Corporation where he was closely involved with the development of xMAP technology. In addition, Dr. McDade was instrumental during this period in securing technology licensing agreements with over 20 strategic partners. He received his Ph.D. in Microbiology from the University of Texas Southwestern Medical School in 1980. Following postdoctoral training at The University of Connecticut Medical Center in Farmington, he held faculty positions at the Rockefeller University in New York and at Louisiana State University School of Medicine in New Orleans.
Paul “Chip” Parkinson, executive vice president for reimbursement strategy, joined the Company in 2016. Previously, he was president of OmedaRx and chief pharmacy officer of Regence Blue Cross Blue Shield health plans. In this role, Mr. Parkinson was responsible for managing $1.7 billion in annual pharmacy spending for the Regence Blue Cross Blue Shield health plans in Utah, Washington, Oregon and Idaho, which have more than two million members. Prior to that, he was vice president, Managed Markets and general manager, Urology at Myriad. During his tenure, Prolaris was included in the NCCN Guidelines for prostate cancer and received Medicare reimbursement. Before joining Myriad, he served in management and managed care leadership roles at Pfizer Inc. Mr. Parkinson received his B.S. degree in Communications from Weber State University.
Bryan Riggsbee, chief financial officer, joined Myriad in October 2014. He previously served 10 years with Laboratory Corporation of America (LabCorp) where his most recent position was as senior vice president of Corporate Finance with responsibility for the financial planning and analysis and treasury functions. Prior to LabCorp, Mr. Riggsbee served in various finance roles with General Electric and began his career in the audit division of KPMG. He received a B.A. in Accounting from North Carolina State University, a B.A. in political science from the University of North Carolina at Chapel Hill and an M.B.A. from Northwestern University. Mr. Riggsbee is a Certified Public Accountant licensed in the State of North Carolina.
Ronald Rogers, executive vice president of corporate communications, joined Myriad in April 2013. He previously served as executive director of Global Media Relations at Merck & Co. Mr. Rogers also worked in communications roles at Johnson & Johnson, Hoechst Marion Roussel, Eli Lilly and Searle and was a business reporter at Chemical & Engineering News. He received an M.S. degree in Communications and a B.S. degree in Public Relations/Chemistry from Illinois State University. He is a member of the National Association of Science Writers.
Bernard Tobin, president of Crescendo Bioscience, joined Myriad in January 2015. He previously held several senior positions at Amgen, including executive director of national accounts, general manager of both the Netherlands and Brazil, and global head of commercial excellence. In addition, he led the global integration of a business development acquisition in more than 100 countries. Prior to that, Mr. Tobin held a variety of leadership roles in the commercial organization at Eli Lilly and Co. He received his B.S. degree in public service and administration from Iowa State University and his M.B.A. from the Fuqua School of Business, Duke University.
Mark Verratti, president of Assurex Health, joined the company in January 2016. He previously served as SVP and chief sales and business development officer at Assurex. Mr. Verratti also held senior leadership positions with Forest Pharmaceuticals where he led commercial teams with revenues approaching $500 million dollars. In addition, he held senior and general management positions with Cyberonics/LivaNova leading teams in over 70 countries. He received a B.S. in Life Sciences with a minor in Physiology from The Pennsylvania State University.